People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Equity Administration Solutions Inc | — | Other Technology | Series B | $25.6M | $651.4M | 2011 |
| Unleash Immuno Oncolytics, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2018 |
Daniel Katzman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Katzman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott Bradley | 1 | 2 |
| Neil Malik | 1 | 2 |
| Mike Boese | 1 | 1 |
| Leslie Leach | 1 | 1 |
| Tami Giovanni | 1 | 1 |
| John Gibbon | 1 | 1 |
| Don Gillotti | 1 | 1 |
| Vito Palmieri | 1 | 1 |
| Gordon Rausser | 1 | 1 |
| Jorge Martin | 1 | 1 |
| Grant Rollin | 1 | 1 |
| Carine Schneider | 1 | 1 |
| Mark Ebersole | 1 | 1 |
| Ariel Muslera | 1 | 1 |
| Ricardo Lisandro Bril | 1 | 1 |
| Bolten Charles | 1 | 1 |
| Steve Madiera | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.